{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:50:19Z","timestamp":1782514219716,"version":"3.54.5"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pregabalin is a gamma-aminobutyric acid (GABA) analog that was approved in the EU in 2004 for the treatment of neuropathic pain, generalized anxiety disorder and epilepsy. Since its introduction, pregabalin abuse and misuse has increased significantly. In Switzerland, clinical reports suggest that pregabalin misuse is common among patients in forensic hospitals and prisons. However, data on pregabalin use is scarce, especially in these settings. Therefore, we conducted a study to explore patterns of pregabalin use among prison and forensic patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used a questionnaire to survey physicians working in prison and forensic medicine in German-speaking countries. A total of 131 responses were received.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>According to the physicians' subjective assessment, 82.5% of them had observed a recent increase in pregabalin use by their patients and 89.1% of them reported that their patients requested pregabalin without a clear medical indication. Patients misusing pregabalin in combination with other illicit substances were observed by 93.3% of the physicians surveyed. According to 73.5% of the physicians surveyed, they had already encountered patients on pregabalin doses of more than 600 mg\/day (the maximum recommended daily dose); the highest dose reported was 4,200 mg\/day. According to 85.0% of physicians surveyed, they have observed patients experiencing withdrawal symptoms from pregabalin, with the most commonly reported symptoms being displeasure and high aggression. Regarding the nationality of pregabalin-misusing patients, 58.3% of the interviewed physicians reported to be rather in contact with foreign patients, mainly from Northwest Africa (Maghreb). Only 45.0% of the surveyed physicians prescribe pregabalin. Among patients who developed behavioral problems while taking pregabalin, none of the physicians (0.0%) showed a tendency to continue pregabalin at the same dose; all respondents chose to reduce\/substitute\/discontinue.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study has provided confirmatory evidence that the use of pregabalin presents a significant issue in forensic and prison medicine across German-speaking countries. Prescribing pregabalin in this field can compound use disorder problems and exacerbate challenges in daily life for those in forensic institutions or prisons. It is necessary that all physicians who prescribe pregabalin are clearly informed about the management (including the risks) of this drug.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2023.1309654","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T04:19:05Z","timestamp":1704687545000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Pregabalin use in forensic hospitals and prisons in German speaking countries\u2014a survey study of physicians"],"prefix":"10.3389","volume":"11","author":[{"given":"Michal","family":"Novotny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Hubl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian Karl Maximilian","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Grosshans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Gutzeit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Bilke-Hentsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Seifritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Mutschler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1080\/02791072.2020.1861392","article-title":"Pregabalin misuse: motives, pattern, and knowledge about its risks among patients in methadone maintenance treatment","volume":"53","author":"Peles","year":"2021","journal-title":"J Psychoactive Drugs"},{"key":"B2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1055\/a-1324-3379","article-title":"Pregabalinmissbrauch und -Abh\u00e4ngigkeit in verschiedenen europ\u00e4ischen L\u00e4ndern im Hinblick auf deren Substitutionspolitik [Pregabalin abuse and dependence in various European countries: Association with substitution policies]","volume":"89","author":"Kuhn","year":"2021","journal-title":"Fortschr Neurol Psychiatr"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1080\/14737175.2016.1202764","article-title":"Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use","volume":"16","author":"Calandre","year":"2016","journal-title":"Expert Rev Neurother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1007\/s00228-013-1578-5","article-title":"Pregabalin abuse among opiate addicted patients","volume":"69","author":"Grosshans","year":"2013","journal-title":"Eur J Clin Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1176\/appi.ajp.2010.09091269","article-title":"Pregabalin abuse, dependence, and withdrawal: a case report","volume":"167","author":"Grosshans","year":"2010","journal-title":"Am J Psychiatry."},{"key":"B6","doi-asserted-by":"publisher","first-page":"107741","DOI":"10.1016\/j.drugalcdep.2019.107741","article-title":"A repeated cross-sectional study of factors associated with pregabalin-positive poisoning deaths in Ireland","volume":"206","author":"Lynn","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/15563650.2021.1892719","article-title":"Increase in pregabalin recreational use in adolescents in France","volume":"59","author":"Dufayet","year":"2021","journal-title":"Clin Toxicol (Phila)."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/add.14412","article-title":"Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings","volume":"114","author":"Cairns","year":"2019","journal-title":"Addiction."},{"key":"B9","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.sapharm.2018.06.018","article-title":"Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: an analysis of the Food and Drug Administration Adverse Events Reporting System (FAERS)","volume":"15","author":"Evoy","year":"2019","journal-title":"Res Social Adm Pharm."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s11096-020-01217-8","article-title":"Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample","volume":"43","author":"Evoy","year":"2021","journal-title":"Int J Clin Pharm."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s40264-020-00985-6","article-title":"Current evidence on abuse and misuse of gabapentinoids","volume":"43","author":"H\u00e4gg","year":"2020","journal-title":"Drug Saf."},{"key":"B12","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s40263-016-0359-y","article-title":"A decade of gabapentinoid misuse: an analysis of the european medicines agency's 'suspected adverse drug reactions' database","volume":"30","author":"Chiappini","year":"2016","journal-title":"CNS Drugs."},{"key":"B13","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/npr2.12195","article-title":"Pregabalin withdrawal in patients without psychiatric disorders taking a regular dose of pregabalin: a case series and literature review","volume":"41","author":"Ishikawa","year":"2021","journal-title":"Neuropsychopharmacol Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40265-020-01432-7","article-title":"Abuse and misuse of pregabalin and gabapentin: a systematic review update","volume":"81","author":"Evoy","year":"2021","journal-title":"Drugs."},{"key":"B15","year":"2023","journal-title":"IQVIA Switzerland Sell-in Data, Channel: Pharmacy, Self-Dispensing Doctors, Hospital"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.4088\/JCP.15l10296","article-title":"Pregabalin use among opioid-addicted patients in Switzerland","volume":"77","author":"Mutschler","year":"2016","journal-title":"J Clin Psychiatry."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e3425","DOI":"10.7759\/cureus.3425","article-title":"Pregabalin-associated discontinuation symptoms: a case report","volume":"10","author":"Naveed","year":"2018","journal-title":"Cureus."},{"key":"B18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.encep.2022.03.003","article-title":"Pr\u00e9gabaline sous la loupe carc\u00e9rale. R\u00e9flexions sur une probl\u00e9matique \u00e9mergente [Pregabalin under the prison lens. Reflections on an emerging issue]","volume":"49","author":"Marcot","year":"2023","journal-title":"Encephale"},{"key":"B19","doi-asserted-by":"publisher","first-page":"S658","DOI":"10.1192\/j.eurpsy.2023.1368","article-title":"Prescription drug abuse in migrants from Middle Eastern and North African countries: a review","volume":"66","author":"Portela","year":"2023","journal-title":"Eur Psychiatr."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0b013e3182872718","article-title":"Concerns about pregabalin: further experience with its potential of causing addictive behaviors","author":"Gahr","year":"2013","journal-title":"J Addict Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1055\/s-0043-122392","article-title":"\u00dcber das Abh\u00e4ngigkeitspotential von Gabapentinoiden [On the risk of dependence on gabapentinoids]","volume":"86","author":"Bonnet","year":"2018","journal-title":"Fortschr Neurol Psychiatr"},{"key":"B22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40122-020-00189-x","article-title":"Gabapentinoid benefit and risk stratification: mechanisms over myth","volume":"9","author":"McAnally","year":"2020","journal-title":"Pain Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1186\/s12888-023-05195-9","article-title":"Prescription drugs with potential for misuse in Irish prisons: analysis of national prison prescribing trends, by gender and history of opioid use disorder, 2012 to 2020","volume":"23","author":"Durand","year":"2023","journal-title":"BMC Psychiatry."},{"key":"B24","doi-asserted-by":"publisher","first-page":"474","DOI":"10.5694\/mja2.50398","article-title":"Management of pregabalin and gabapentin prescribing and use in NSW prisons","volume":"211","author":"Nicholls","year":"2019","journal-title":"Med J Aust"},{"key":"B25","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40265-021-01494-1","article-title":"Comment on \u201cabuse and misuse of pregabalin and gabapentin: a systematic review update\u201d","volume":"81","author":"Bonnet","year":"2021","journal-title":"Drugs."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s40263-016-0390-z","article-title":"Pregabalin for the treatment of drug and alcohol withdrawal symptoms: a comprehensive review","volume":"30","author":"Freynhagen","year":"2016","journal-title":"CNS Drugs."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1309654\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T04:19:08Z","timestamp":1704687548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1309654\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":26,"alternative-id":["10.3389\/fpubh.2023.1309654"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1309654","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"article-number":"1309654"}}